eConsent is a key vehicle for change, and not simply to improve trial efficiency
![consent-form consent-form](https://icon.widen.net/content/lganm6v9oc/original/consent-form.png?u=z8skf3)
Which would you prefer?
Which do you think patients prefer: the excerpt below from a 23-page, informed consent document or the same information presented in visual format in the following video?
Unsurprisingly research has shown that patients prefer to learn about the trial through the more accessible medium of video. Not only do patients favour the video, but the information provided in this format is more easily understood which leads to better trust in the process and most importantly facilitates a trusted relationship with the investigator. This instilled trust has the potential to be transformative in clinical trials.
I have drawn inspiration for an innovative informed consent process from my time working alongside Charles Spinosa, a business consultant known for transforming trust between a company, its customers, and its employees. Spinosa studied how relationships change based on trust, built from everyday interactions and implicit expectations. Based on this knowledge, Spinosa has turned around businesses such as ADP, Hospital for Special Surgery, and CEMEX. (The latter case won fame from its description by Chan Kim and Renée Mauborgne the Blue Ocean Strategy.)
Are we missing an opportunity to build trust in the consent process that can substantially improve recruitment, retention, and compliance rates? eConsent is a key vehicle for change, and not simply to improve trial efficiency (e.g., time savings from biometric signature capture and validation), the true potential of eConsent lies in the opportunity to improve patient comprehension about the trial’s procedures and educate patients in a more personal and comfortable way. Through an eConsent platform, patients can learn about a trial by watching informative videos at their own pace, rather than reading a long document. Patients who are empowered by information that they can understand are more likely to ask personally relevant questions of clinicians, feel confident in getting answers and having generally more transparency throughout the trial.
Infusing this crucial conversation with trust prevents patients from entering a trial blindly — which can have implications for retention. Thus, the transformative potential of eConsent stems not just from efficiency in administration, but from improving how patients understand the treatment they will receive, what their participation involves and how they are protected within the framework of the clinical trial consent.
At ICON we have designed videos, similar to the clip at the top of this blog, for our Firecrest Patient Portal that provide patients with more easily comprehensible (and retainable) information. This enables what we term “truly informed consent.”
Empirical research on multimedia consent assets, performed by Baruch Fischhoff, Ph.D. at Carnegie Mellon University (and sponsored by ICON), is revealing insights that make for better patient centric trials. Fischhoff’s research is continuing and a full report will be available later this year upon study completion.
In this section
-
Digital Disruption
- AI and clinical trials
-
Clinical trial data anonymisation and data sharing
-
Clinical Trial Tokenisation
-
Closing the evidence gap: The value of digital health technologies in supporting drug reimbursement decisions
-
Digital disruption in biopharma
-
Disruptive Innovation
- Remote Patient Monitoring
-
Personalising Digital Health
- Real World Data
-
The triad of trust: Navigating real-world healthcare data integration
-
Patient Centricity
-
Agile Clinical Monitoring
-
Capturing the voice of the patient in clinical trials
-
Charting the Managed Access Program Landscape
-
Developing Nurse-Centric Medical Communications
- Diversity and inclusion in clinical trials
-
Exploring the patient perspective from different angles
-
Patient safety and pharmacovigilance
-
A guide to safety data migrations
-
Taking safety reporting to the next level with automation
-
Outsourced Pharmacovigilance Affiliate Solution
-
The evolution of the Pharmacovigilance System Master File: Benefits, challenges, and opportunities
-
Sponsor and CRO pharmacovigilance and safety alliances
-
Understanding the Periodic Benefit-Risk Evaluation Report
-
A guide to safety data migrations
-
Patient voice survey
-
Patient Voice Survey - Decentralised and Hybrid Trials
-
Reimagining Patient-Centricity with the Internet of Medical Things (IoMT)
-
Using longitudinal qualitative research to capture the patient voice
-
Agile Clinical Monitoring
-
Regulatory Intelligence
-
An innovative approach to rare disease clinical development
- EU Clinical Trials Regulation
-
Using innovative tools and lean writing processes to accelerate regulatory document writing
-
Current overview of data sharing within clinical trial transparency
-
Global Agency Meetings: A collaborative approach to drug development
-
Keeping the end in mind: key considerations for creating plain language summaries
-
Navigating orphan drug development from early phase to marketing authorisation
-
Procedural and regulatory know-how for China biotechs in the EU
-
RACE for Children Act
-
Early engagement and regulatory considerations for biotech
-
Regulatory Intelligence Newsletter
-
Requirements & strategy considerations within clinical trial transparency
-
Spotlight on regulatory reforms in China
-
Transfer of marketing authorisation
-
An innovative approach to rare disease clinical development
-
Therapeutics insights
- Endocrine and Metabolic Disorders
- Cardiovascular
- Cell and Gene Therapies
- Central Nervous System
-
Glycomics
- Infectious Diseases
- NASH
-
Oncology
- Paediatrics
-
Respiratory
-
Rare and orphan diseases
-
Advanced therapies for rare diseases
-
Cross-border enrollment of rare disease patients
-
Crossing the finish line: Why effective participation support strategy is critical to trial efficiency and success in rare diseases
-
Diversity, equity and inclusion in rare disease clinical trials
-
Identify and mitigate risks to rare disease clinical programmes
-
Leveraging historical data for use in rare disease trials
-
Natural history studies to improve drug development in rare diseases
-
Patient Centricity in Orphan Drug Development
-
The key to remarkable rare disease registries
-
Advanced therapies for rare diseases
-
Transforming Trials
-
Accelerating biotech innovation from discovery to commercialisation
-
Ensuring the validity of clinical outcomes assessment (COA) data: The value of rater training
-
Linguistic validation of Clinical Outcomes Assessments
-
Optimising biotech funding
- Adaptive clinical trials
-
Best practices to increase engagement with medical and scientific poster content
-
Decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
Decentralised and Hybrid clinical trials
-
Practical considerations in transitioning to hybrid or decentralised clinical trials
-
Navigating the regulatory labyrinth of technology in decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
eCOA implementation
- Flexible delivery models
-
Implications of COVID-19 on statistical design and analyses of clinical studies
-
Improving pharma R&D efficiency
-
Increasing Complexity and Declining ROI in Drug Development
-
Innovation in Clinical Trial Methodologies
- Partnership insights
-
Risk Based Quality Management
-
Transforming the R&D Model to Sustain Growth
-
Accelerating biotech innovation from discovery to commercialisation
-
Value Based Healthcare
-
Strategies for commercialising oncology treatments for young adults
-
US payers and PROs
-
Accelerated early clinical manufacturing
-
Cardiovascular Medical Devices
-
CMS Part D Price Negotiations: Is your drug on the list?
-
COVID-19 navigating global market access
-
Ensuring scientific rigor in external control arms
-
Evidence Synthesis: A solution to sparse evidence, heterogeneous studies, and disconnected networks
-
Global Outcomes Benchmarking
-
Health technology assessment
-
Perspectives from US payers
-
ICER’s impact on payer decision making
-
Making Sense of the Biosimilars Market
-
Medical communications in early phase product development
-
Navigating the Challenges and Opportunities of Value Based Healthcare
-
Payer Reliance on ICER and Perceptions on Value Based Pricing
-
Payers Perspectives on Digital Therapeutics
-
Precision Medicine
-
RWE Generation Cross Sectional Studies and Medical Chart Review
-
Survey results: How to engage healthcare decision-makers
-
The affordability hurdle for gene therapies
-
The Role of ICER as an HTA Organisation
-
Strategies for commercialising oncology treatments for young adults
-
Blog
-
Videos
-
Webinar Channel